These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 34387901

  • 1. Retrospective evaluation of a dose-dependent effect of angiotensin-converting enzyme inhibitors on long-term outcome in dogs with cardiac disease.
    Ward JL, Chou YY, Yuan L, Dorman KS, Mochel JP.
    J Vet Intern Med; 2021 Sep; 35(5):2102-2111. PubMed ID: 34387901
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease.
    Ames MK, Atkins CE, Eriksson A, Hess AM.
    J Vet Cardiol; 2017 Jun; 19(3):218-227. PubMed ID: 28576479
    [Abstract] [Full Text] [Related]

  • 4. Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.
    de Madron E, King JN, Strehlau G, White RV.
    Can Vet J; 2011 Nov; 52(11):1219-25. PubMed ID: 22547843
    [Abstract] [Full Text] [Related]

  • 5. Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease.
    Thomason JD, Rockwell JE, Fallaw TK, Calvert CA.
    J Vet Cardiol; 2007 Nov; 9(2):103-8. PubMed ID: 17983885
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2008 Nov; 22(5):1124-35. PubMed ID: 18638016
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
    Häggström J, Hansson K, Karlberg BE, Kvart C, Madej A, Olsson K.
    Am J Vet Res; 1996 Nov; 57(11):1645-52. PubMed ID: 8915446
    [Abstract] [Full Text] [Related]

  • 14. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST).
    Coffman M, Guillot E, Blondel T, Garelli-Paar C, Feng S, Heartsill S, Atkins CE.
    J Vet Intern Med; 2021 Jul; 35(4):1673-1687. PubMed ID: 34028078
    [Abstract] [Full Text] [Related]

  • 15. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy.
    O'Grady MR, Minors SL, O'Sullivan ML, Horne R.
    J Vet Intern Med; 2008 Jul; 22(4):897-904. PubMed ID: 18537880
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacogenetic Risk Stratification in Angiotensin-Converting Enzyme Inhibitor-Treated Patients with Congestive Heart Failure: A Retrospective Cohort Study.
    Nelveg-Kristensen KE, Busk Madsen M, Torp-Pedersen C, Køber L, Egfjord M, Berg Rasmussen H, Riis Hansen P.
    PLoS One; 2015 Jul; 10(12):e0144195. PubMed ID: 26633885
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin-converting enzyme inhibitors in preclinical myxomatous mitral valve disease in dogs: systematic review and meta-analysis.
    Donati P, Tarducci A, Zanatta R, Verdier N, Belerenian G, Cordero I, Villalta C, Franco J, Tarragona L.
    J Small Anim Pract; 2022 May; 63(5):362-371. PubMed ID: 34905219
    [Abstract] [Full Text] [Related]

  • 19. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency.
    Atkins CE, Keene BW, Brown WA, Coats JR, Crawford MA, DeFrancesco TC, Edwards NJ, Fox PR, Lehmkuhl LB, Luethy MW, Meurs KM, Petrie JP, Pipers FS, Rosenthal SL, Sidley JA, Straus JH.
    J Am Vet Med Assoc; 2007 Oct 01; 231(7):1061-9. PubMed ID: 17916031
    [Abstract] [Full Text] [Related]

  • 20. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ, Block CL, Laughlin DS, Oyama MA.
    J Vet Intern Med; 2018 Sep 01; 32(5):1509-1516. PubMed ID: 30216549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.